All In Biotech

Drug Trial Radar · NCT07807059

A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Mar 15, 2027

Study completion Mar 15, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8 healthy participants.

Conditions

  • Overweight/Obesity
  • Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
  • Type 2 Diabetes Mellitus

Interventions

  • HRS-4729Drug

    Each subject will receive a single subcutaneous dose of HRS-4729 injection solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: assessed up to approximately 4 weeks post-dose;
  2. AUC0-tTime frame: assessed up to approximately 4 weeks post-dose
  3. AUC0-inf.Time frame: assessed up to approximately 4 weeks post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.